

## DAPAGLIFLOZIN tablets (Forxiga®) for heart failure with reduced ejection fraction

**The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of DAPAGLIFLOZIN tablets (Forxiga®) for heart failure with reduced ejection fraction.**

### GREY

Dapagliflozin is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.<sup>[1]</sup>

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of heart failure should continue to follow national guidance, local pathways and local formulary choices:

- > NICE Guideline NG106: [Chronic heart failure in adults: diagnosis and management](#) (12 September 2018)
- > Pan Mersey Formulary Chapter 2: [Cardiovascular system](#)

### References

1. AstraZeneca UK Limited. Summary of Product Characteristics; [Forxiga 10 mg film-coated tablets](#) , 03 November 2020. Accessed online 16 November 2020.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.